APCI tracks and reports on pharmacy public policy developments, including PBM reform efforts, legislative activity, and regulatory changes impacting independent pharmacies.
APCI tracks and reports on pharmacy public policy developments, including PBM reform efforts, legislative activity, and regulatory changes impacting independent pharmacies.
APCI looks back at a pivotal year for PBM reform, including the introduction of the Pharmacists Fight Back Act, growing congressional support, national policy events, state-level advocacy, and APCI’s ongoing efforts to protect independent pharmacies and their patients.
Watch top moments from lawmakers in 2024 calling out PBM abuses and pushing for meaningful reform.
Bipartisan lawmakers highlight growing momentum for the Pharmacists Fight Back Act, with a press conference underscoring support for comprehensive PBM reform.
Miss the webcast? Watch the full Pharmacists Fight Back Act overview and take action by urging your Representative to support the bill.
The closure of a Georgia independent pharmacy highlights stark PBM reimbursement disparities, sparking outrage from lawmakers and renewed calls for reform.
APCI urges the DOJ to block Optum’s acquisition of Amedisys, warning that deeper insurer-PBM integration threatens competition, patient choice, and the integrity of care.
APCI endorses bipartisan legislation to end PBM spread pricing in Medicaid, calling it a critical step toward transparency, fair reimbursement, and lower costs for patients and taxpayers.
BESSEMER, Ala. (Sept. 20) – A judge’s decision to allow the merger between UnitedHealth Group and Change Healthcare to move forward is likely to prove detrimental to patients, providers, and… Read More »
APCI urges federal regulators to block Prime Therapeutics’ acquisition of Magellan Rx, warning it would reduce competition and worsen prescription drug pricing and access.
APCI urges the FTC to investigate PBM practices, citing widespread anti-competitive behavior that drives up drug costs and limits patient access.